Introduction: Merkel cell carcinoma is a neuroendocrine malignancy. Suppressor of Electronic supplementary material The online version of this article (
fused (SUFU) is a tumor suppressor oncogene that participates in the Hedgehog (Hh) signaling pathway. The aim of the study was to describe a patient whose Merkel cell carcinoma demonstrated a SUFU genomic alteration.
Case Study: The Hh signaling pathway is involved in the pathogenesis of several tumors, including nevoid basal cell carcinoma syndrome that is associated with an alteration of the patched-1 (PTCH1) gene. Targeted molecular therapy against smoothened (SMO) with vismodegib has been shown to be an effective therapeutic intervention for patients with PTCH-1 mutation. 
INTRODUCTION
Merkel cell carcinoma is an aggressive neuroendocrine cancer of the skin [1] .
Suppressor of fused (SUFU), an integral component of the Hedgehog (Hh) signaling pathway, functions as a tumor suppressor gene [2] . A man with metastatic Merkel cell carcinoma is described whose tumor was associated with a SUFU genomic aberration.
Potential therapeutic interventions based upon this unique abnormality of his tumor are postulated. A 66- Cutaneous examination (1 month after the lymph node biopsy and 6 months after the patient's discovery of a left buttock mass) showed a painless flesh-colored 3 9 3 cm subcutaneous nodule with central erythema on his left buttock (Fig. 1 ). The nodule was firmly grasped and pushed toward the skin surface as a punch biopsy using a 4-mm circular blade was performed into its center. A cylindrical core specimen of tissue, extending from the epidermis to beyond the deep dermis, was obtained. The nodule was then firmly squeezed and additional aggregates of tumor (appearing yellowish-white and blood tinged) that extruded through the biopsy wound were collected ( Fig. 2 ).
CASE REPORT
Microscopic examination of the skin biopsy specimen showed an infiltrate of small blue cells with minimal cytoplasm in the deep portion of the punch biopsy and all the pieces of subcutaneous tissue (Fig. 3 ). The basophilic cells were uniform in size with a vesicular nucleus and small nucleoli. Numerous mitoses were appreciated and there were large areas of necrosis. The tumor invaded fascia in the deeper specimens and focally grew in close approximation to multiple blood vessels; however, no intravascular or perineural invasion was identified ( Fig. 4) .
Immunohistochemical studies showed that the tumor cells stained positive for cytokeratin 20 (in a cytoplasmic and paranuclear dot-like pattern), CD56 (neural cell adhesion molecule), and synaptophysin ( Fig. 5 ). The tumor cells were negative for prostate-specific antigen and thyroid transcription factor 1. All genes known to be somatically altered in human solid tumors that are validated targets for therapy, either approved or in clinical trials, and/or that are unambiguous drivers of oncogenesis were included. The assay interrogated 315 genes as well as introns of 28 genes involved in rearrangements determined by focal assembly; gene copy number alterations (amplification), by comparison to process matched normal controls; and gene fusions/rearrangements, by clustering chimeric reads mapped to targeted introns. Amplifications were called for C6 copies except for ErbB2 (C5 copies). Six to seven copy numbers are called as equivocal and C8 are definitive; for ErbB2, equivocal amplification was 5-7 copies; all (equivocal or definitively amplified) were designated as positive for amplification in our patient.
Aberrations, mutations or other alterations in kinases that were presumed to be inactivating based on wet lab experiments or structural modeling were not included [5] . Follow-up evaluation shows decrease in the size of the left buttock tumor and the previously enlarged lymph nodes. Consideration to use experimental agents that target the distal Hh pathway may be considered if his tumor progresses.
Informed consent was obtained from the patient for being included in the study and for publication of the images.
DISCUSSION

Merkel Cell Carcinoma
Merkel cell carcinoma was initially described by Toker in 1972 as trabecular carcinoma of the skin [1] . It is a biologically aggressive tumor with a poor prognostic outcome resulting from local, regional and distant recurrences. Older men are more commonly affected and the primary tumor is usually located on sunexposed skin [1, 6, 7] .
Merkel cell carcinoma usually presents as an asymptomatic rapidly enlarging flesh-colored or blue-red nodule [6, 8] . In our patient, the tumor clinically appeared as a firm red nodule below the skin surface. Its gross appearance, yellow- [17] . Indeed, there is improved survival for patients whose Merkel cell carcinoma is virus-positive as compared individuals with virus-negative tumors [14, 18] . However, the presence of Merkel cell polyomavirus is not specific for Merkel cell carcinoma. The virus has also been demonstrated in other malignancies, including cervical carcinoma [19] , chronic lymphocytic leukemia [20] , cutaneous squamous cell carcinoma [21] , folliculotropic mycosis fungoides [22, 23] , Langerhans cell sarcoma [24] , and small cell carcinoma (extrapulmonary [25] and parotid [26] ). In addition, although one group of researchers have found an association between Merkel cell polyomavirus infection and epidermal growth factor hotspot mutations in non-small-cell lung cancer [27] , there is currently no evidence of an association between the virus and any specific genomic aberration-including a mutation in SUFU protein-in Merkel cell carcinoma [28] . Mutational analysis of Merkel cell carcinoma has revealed numerous abnormalities including mutations in telomerase activation, tumor suppressors, and tyrosine kinase signaling ( Merkel cell carcinoma related to a genomic aberration of the Hh signaling pathway has previously been described.
Hedgehog Signaling Pathway
The Hh signaling pathway has an essential role in not only embryonic development but also cell differentiation and proliferation. The term has been demonstrated to contribute not only to the maintenance and expression of leukemic stem cells, but also to chemotherapy resistance (in ovarian cancer, cervical cancer, and myeloid leukemia cells) and radiotherapy resistance (in pancreatic cancer and head and neck cancer) [2, 32, 38, 39] .
Targeted therapy that affects the Hh signaling pathway-specifically with vismodegib that is an inhibitor of SMO-has shown efficacy in the treatment of locally advanced and metastatic basal cell carcinoma and other tumors with patched-1 mutations [34, 36, [40] [41] [42] [43] [44] [45] . However, some patients' basal cell carcinomas have acquired resistance to vismodegib [33, 46, 47] . Therefore, therapeutic agents that target downstream molecules in the Hh signaling pathway, distal to SMO, are being developed [38] .
Suppressor of Fused Protein
SUFU is an intracellular negative regulator of the Hh signaling pathway. It is a tumor suppressor protein. SUFU functions by modulating the activity of glioma transcription factors [48] [49] [50] [51] . SUFU mutation (R299Q), as seen in our patient, has previously been described in other cancers [52] .
Mutations of SUFU have also been discerned in patients with either idiopathic or nevoid basal cell carcinoma syndrome-associated medulloblastomas [53] [54] [55] [56] [57] [58] [59] [60] [61] . Less than one percent (3/351) 
